Biogenvs.Regeneron
BIIB vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 2.4× larger than Biogen by market cap; Regeneron trades at the lower P/E (15.7 vs 21.3); year to date, Biogen leads (+13.2% vs −13.9%).
Side by side
| BIIB | REGN | |
|---|---|---|
| Market cap | $29.3B | $69.7B |
| Price | $199.15 | $664.52 |
| Today | +0.1% | −0.5% |
| Return YTD | +13.2% | −13.9% |
| Return 1Y | +47.2% | +18.7% |
| P/E | 21.3 | 15.7 |
| P/S | 2.9 | 4.7 |
| P/B | 1.6 | 2.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BiogenBIIB
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Full BIIB profile →RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →More comparisons in Biotech & innovation
See where BIIB and REGN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →